Catalent, Inc.

How this company captures the theme economics

Competitive position

A top-tier global contract development and manufacturing organization (CDMO) and one of the largest independent providers of sterile drug-product fill-finish (vials, prefilled syringes, cartridges), biologics drug substance/drug product, and oral, softgel, and orally disintegrating dose technologies. The FY2023 10-K states it serves more than 1,200 customers in more than 80 countries, with about 35% of FY2023 net revenue generated outside the US. It competes with Lonza, Thermo Fisher (Patheon), Samsung Biologics, and WuXi, differentiating on installed regulator-approved sterile capacity, breadth of dose formats, and proprietary delivery technologies; FY2023 also showed cyclical strain (a net loss) as COVID-era volumes rolled off.

Scarce assets

Installed, cGMP-qualified sterile fill-finish capacity is the core scarce asset: high-speed vial, syringe, and cartridge lines run under barrier-isolator/aseptic conditions that take years, heavy capital (FY2023 capital expenditures were $594 million), and FDA/EMA approval to replicate. The FY2023 10-K notes two large-scale facilities (Bloomington, Indiana and Harmans, Maryland) together generate a material portion of net revenue. A base of roughly 8,000 qualified products and proprietary oral/softgel delivery technologies add switching costs. Caveat: three flagship sterile fill-finish sites (Anagni, Bloomington, Brussels) were transferred to Novo Nordisk at the acquisition, reducing the remaining independent third-party fill-finish footprint.

Products, segments, and customers

Two reportable segments. Biologics (biologics drug substance, drug-product fill-finish, and cell & gene therapy) had FY2023 net revenue of $1,978 million (about 46% of aggregate segment revenue before inter-segment eliminations). Pharma and Consumer Health (oral and softgel dose forms, clinical supply services, and consumer self-care/OTC) had FY2023 net revenue of $2,287 million. Customers span large pharma, biotech, and consumer health across more than 80 countries, with roughly 35% of FY2023 net revenue generated outside the US.

Theme capture

Catalent captures essential-medicine manufacturing-resilience economics as the contracted final-step manufacturer, converting partners' bulk drug substance into finished sterile injectable doses at capacity-constrained aseptic lines. This bottleneck role was demonstrated at scale during COVID-19: commercial fill-finish for Moderna at Bloomington (an initial 100 million doses under barrier-isolator technology) and, per trade reporting, for AstraZeneca and Johnson & Johnson at Anagni, Italy. The same capacity scarcity drove Novo Holdings' take-private and Novo Nordisk's acquisition of the Anagni, Bloomington, and Brussels fill-finish sites to secure GLP-1 finishing capacity - which also shifts some fill-finish capacity toward captive parent-group use.

What must be true

1. Sterile fill-finish and biologics drug-product capacity remains structurally supply-constrained, sustaining high utilization and pricing power at Catalent's aseptic lines.
2. The post-carve-out remaining Catalent retains a viable third-party (merchant) CDMO franchise despite now being owned by a pharma competitor (Novo), i.e., non-Novo customers do not materially defect over capacity-allocation or confidentiality concerns.
3. Key sterile sites (notably Bloomington and Harmans) sustain regulatory/quality compliance and avoid FDA warning letters or import alerts that would halt supply.

Identifiable catalysts

• Completion and integration of Novo Nordisk's acquisition of the Anagni, Bloomington, and Brussels fill-finish sites and the associated GLP-1 capacity ramp.
• New or expanded third-party fill-finish and biologics contracts, and further capacity additions, signaling durability of the merchant-CDMO franchise.
• Any Novo Holdings decision to issue registered public debt or pursue a future relisting that would restore disclosed, investable access.

Where the evidence lands

Catalent remains a strategically relevant CDMO reference, but it has been private since December 18, 2024, and three named fill-finish sites are owned and operated by Novo Nordisk. Current Catalent network economics, third-party capacity and valuation are not publicly disclosed. No reviewer has accepted the subject; it remains NOT_READY.

Next diligence

1. Confirm whether Catalent has registered/public debt still outstanding (its 2027/2028/2029/2030 senior notes) that would provide investable, disclosed exposure with ongoing bondholder or SEC reporting, and review indenture/covenant terms.
2. Pull FDA establishment inspection histories (Form 483s / EIRs) for Catalent's sterile sites to assess current quality/compliance status.
3. Secure Novo Holdings / Novo Nordisk disclosures on Catalent integration, capacity allocation, and completion of the three-site fill-finish carve-out and the go-forward third-party vs. captive revenue mix.
4. Access licensed private-market/credit data for current leverage, EBITDA, and any indicative valuation of the private entity, and retrieve the FY2024 10-K figures from a primary source once accessible.